GlassScriptPhysician profile
Paul M Littman
NPI 1538364369
$13,636.32
in general payments reported to CMS, 2019-2025
27 companies · $473 in 2025
The $473 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,656 · 2020: $3,271 · 2021: $3,304 · 2022: $1,409 · 2023: $131 · 2024: $2,393 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,918 · Food and Beverage: $886 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,917.64 |
| Food and Beverage | $886.28 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $7,826.00 | 2019-2022 | |
| Axonics, INC. | $2,897.63 | 2020-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $889.77 | 2019-2025 | Veozah |
| Valencia Technologies Corporation | $822.55 | 2022 | |
| Intuitive Surgical, INC. | $165.00 | 2021 | |
| Boston Scientific Corporation | $133.73 | 2019-2022 | |
| Abbvie INC. | $124.82 | 2019-2025 | |
| Zyla Life Sciences, INC. | $95.44 | 2019-2020 | |
| Medtronic USA, INC. | $90.92 | 2020 | |
| Allergan, INC. | $71.85 | 2019-2021 | |
| Coloplast Corp | $66.71 | 2019-2021 | |
| Millicent US INC | $65.86 | 2019-2025 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $50.13 | 2019-2021 | |
| Amgen INC. | $43.56 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $41.22 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $39.12 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $36.82 | 2025 | Gemtesa |
| Hollister Incorporated | $27.53 | 2019-2021 | |
| Teleflex LLC | $25.89 | 2024 | Solesta |
| Mayne Pharma Commercial LLC | $24.70 | 2021 | |
| Abc Home Medical Supply, INC. | $15.98 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.76 | 2025 | Exparel |
| Olympus America INC. | $15.08 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.94 | 2019 | |
| Daiichi Sankyo INC. | $13.12 | 2020 | |
| Escala Medical INC. | $12.10 | 2025 | |
| Pfizer INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Littman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.